ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Jumpcode Genomics ('Jumpcode'), a life science tools company ...
Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients
The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.
AI in life sciences raises various patent law considerations, including subject matter eligibility, novelty/obviousness, and ...
Expanding CRISPR's Potential Since its discovery, CRISPR (“Clustered Regularly Interspaced Short Palindromic Repeats”), which ...
CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...
While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback